 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Xceleron Ltd
|
-
New Data Further Strengthens Case for Microdosing in Drug Development
(25 Jun 2008)
EUMAPP consortium present data on 7 compounds
Xceleron announced that preliminary results from the European Union Microdose AMS Partnership Programme (EUMAPP) further endorses the growing body of microdose data that predicts pharmacological dose ADME/PK outcomes.The EUMAPP consortium presented ...
-
Xceleron and Organon sign microdose study agreement
(12 Sep 2007)
Xceleron Ltd announced a collaboration with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development. Xceleron has been selected by Organon ...
-
Corcept Therapeutics and Xceleron sign agreement for microdosing study using accelerator mass spectrometry
(27 Jul 2007)
Corcept Therapeutics and Xceleron announced an agreement for a human microdosing study of one of Corcept's new chemical entities, a selective GR-II antagonist, utilizing Xceleron's Accelerator Mass Spectrometry (AMS) technology.In early 2003, ...
-
Xceleron expands U.S. operations
(25 Jul 2007)
Multimillion dollar technology and jobs investment in Maryland
Xceleron announced a major milestone in the development of its US business with the signing of a lease on a multimillion dollar facility in Germantown, Maryland. The state-of-the-art facility will open in November 2007 housing a new accelerator mass ...
-
Xceleron and Covance enter co-promotional agreement
(17 Nov 2006)
Xceleron announced a cooperation agreement with Covance in which both companies will make available each others drug development services to their customers. In addition Xceleron and Covance will carry out joint projects on behalf of sponsors and to ...
-
Xceleron scientific advisory board expanded
(23 Oct 2006)
Xceleron announced that it has brought in two new members to expand its scientific advisory board (SAB) under the chairmanship of Professor Malcolm Rowland. The board's role is to advise the company on further developing its core drug development ...
-
Xceleron expands US operation with multimillion dollar investment in new facilities
(08 Sep 2006)
Xceleron announced a new multimillion dollar investment to create its first pharmaceutical testing facilities in the U.S. With up to 50% of global demand for drug and metabolite analysis coming from the U.S. Xceleron will invest up to $7.5m on the ...
-
Xceleron sign an agreement with Biofrontera Bioscience GmbH to accelerate drug development using microdosing
(19 Jul 2006)
Xceleron, a service provider specialising in zeptoanalysis to accelerate drug development, announce an agreement for a Phase 0 microdose study with Biofrontera Bioscience GmbH, a member of the German Biofrontera Group, specializing in the ...
Additional information
Xceleron Ltd
Heslington, York, United Kingdom
Company
|
|
|
|
|
|
Top
